How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Specialty Pharmacy Services Market
- By Service Type: Medication Therapy Management (MTM), Specialty Drug Distribution, Patient Adherence Programs, Clinical Support Services, Reimbursement and Benefit Verification
- By Therapeutic Area: Oncology, Rheumatology, HIV/AIDS, Multiple Sclerosis, Hepatitis C, Cystic Fibrosis
- By End User: Hospitals and Health Systems, Physician Offices, Home Healthcare Providers, Retail Pharmacies, Long-term Care Facilities
- By Distribution Channel: Direct-to-Patient Delivery, Physician Dispensing, Retail Pharmacy Dispensing, Mail Order Pharmacy
- By Payer Type: Commercial Insurance, Medicare Part D, Medicaid, Self-Pay Patients, Pharmacy Benefit Managers (PBMs)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Medication Therapy Management (MTM) leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.185 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.193 →
Full report · locked preview
Everything inside the Specialty Pharmacy Services Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
Therapeutic Area 6
End User 5
Distribution Channel 4
Payer Type 5
Companies profiled
CVS Health Specialty Pharmacy
OptumRx (UnitedHealth Group)
Express Scripts Specialty Pharmacy (Cigna)
Walgreens Boots Alliance Specialty Pharmacy
Accredo Specialty Pharmacy (Express Scripts)
Diplomat Pharmacy (now part of OptumRx)
BioScrip Inc.
Kaiser Permanente Specialty Pharmacy
Rite Aid Specialty Pharmacy
Humana Specialty Pharmacy
Magellan Rx Management
Aetna Specialty Pharmacy (CVS Health)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →CVS Health Specialty Pharmacy
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →OptumRx (UnitedHealth Group)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Express Scripts Specialty Pharmacy (Cigna)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Walgreens Boots Alliance Specialty Pharmacy
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Accredo Specialty Pharmacy (Express Scripts)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Diplomat Pharmacy (now part of OptumRx)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →BioScrip Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Kaiser Permanente Specialty Pharmacy
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Rite Aid Specialty Pharmacy
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Humana Specialty Pharmacy
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Magellan Rx Management
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Aetna Specialty Pharmacy (CVS Health)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →AllianceRx Walgreens Prime
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →PillPack (Amazon)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Avella Specialty Pharmacy
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$12,254M by 2033 · 11.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Medication Therapy Management (MTM)63.5
- Specialty Drug Distribution9.2
- Patient Adherence Programs10.0
- Clinical Support Services8.3
- Reimbursement and Benefit Verification9.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,700M → $4,035M · 11.4%
Europe$1,185M → $2,857M · 11.6%
Asia Pacific$1,082M → $2,369M · 10.3%
Latin America$669.7M → $1,768M · 12.9%
Middle East and Africa$515.2M → $1,272M · 12.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.382026
11.402027
11.422028
11.432029
11.442030
11.452031
11.462032
11.482033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- CVS Health Specialty Pharmacy19.5
- OptumRx (UnitedHealth Group)17.9
- Express Scripts Specialty Pharmacy (Cigna)8.4
- Walgreens Boots Alliance Specialty Pharmacy7.3
- Accredo Specialty Pharmacy (Express Scripts)9.2
- Diplomat Pharmacy (now part of OptumRx)9.6
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type20.2%
Therapeutic Area18.5%
End User18.9%
Distribution Channel21.2%
Payer Type21.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe23.2
- Asia Pacific19.3
- Latin America14.4
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| CVS Health Specialty Pharmacy | 89 | 83 | 82 | 78 | 84 | 74 | 82 |
| OptumRx (UnitedHealth Group) | 74 | 73 | 71 | 91 | 74 | 82 | 78 |
| Express Scripts Specialty Pharmacy (Cigna) | 83 | 68 | 88 | 82 | 80 | 79 | 80 |
| Walgreens Boots Alliance Specialty Pharmacy | 64 | 75 | 57 | 77 | 71 | 70 | 69 |
| Accredo Specialty Pharmacy (Express Scripts) | 54 | 57 | 51 | 53 | 75 | 74 | 61 |
| Diplomat Pharmacy (now part of OptumRx) | 47 | 68 | 63 | 52 | 62 | 56 | 58 |
| BioScrip Inc. | 55 | 50 | 44 | 51 | 51 | 51 | 50 |
| Kaiser Permanente Specialty Pharmacy | 37 | 43 | 39 | 59 | 58 | 60 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- CVS Health Specialty Pharmacy
- OptumRx (UnitedHealth Group)
- Express Scripts Specialty Pharmacy (Cigna)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| CVS Health Specialty Pharmacy | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| OptumRx (UnitedHealth Group) | ✓ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Express Scripts Specialty Pharmacy (Cigna) | ✓ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Walgreens Boots Alliance Specialty Pharmacy | ◐ | ◐ | − | ◐ | − | − |
| Accredo Specialty Pharmacy (Express Scripts) | ◐ | − | ◐ | − | ✓ | ◐ |
| Diplomat Pharmacy (now part of OptumRx) | − | ✓ | ◐ | − | ◐ | − |
| BioScrip Inc. | ◐ | ◐ | − | − | − | − |
| Kaiser Permanente Specialty Pharmacy | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1CVS Health Specialty Pharmacy82
2Express Scripts Specialty Pharmacy (Cigna)80
3OptumRx (UnitedHealth Group)78
4Walgreens Boots Alliance Specialty Pharmacy69
5Accredo Specialty Pharmacy (Express Scripts)61
6Diplomat Pharmacy (now part of OptumRx)58
7BioScrip Inc.50
8Kaiser Permanente Specialty Pharmacy49
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
CVS Health Specialty PharmacyOptumRx (UnitedHealth Group)Express Scripts Specialty Pharmacy (Cigna)
Challenger1
Strong scale, closing on the leaders.
Walgreens Boots Alliance Specialty Pharmacy
Contender2
Focused players with pockets of strength.
Accredo Specialty Pharmacy (Express Scripts)Diplomat Pharmacy (now part of OptumRx)
Niche2
Specialists in a single segment or region.
BioScrip Inc.Kaiser Permanente Specialty Pharmacy
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Specialty Pharmacy Services Market — a $599M beachhead inside a $9.39B market.
Beachhead (SOM)$599Mobtainable near-term
Serviceable (SAM)$3.65Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Medication Therapy Management (MTM)
Best fit — highest urgency & budget in Service Type.
Economic buyer75 fit
Specialty Drug Distribution
Strong fit — clear ROI and a fast path to value.
End user67 fit
Patient Adherence Programs
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Area & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel27%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Specialty Pharmacy Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified22%
Evaluation14%
Closed-won8%
$16.9KCAC
$93KLTV
5.5:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Specialty Pharmacy Services Market is a durable-growth opportunity — $925M by 2033, compounding at 9.8%.
TAM · 2025$438Mtoday
TAM · 2033$925Mforecast
CAGR9.8%2027–2033
Cumulative$5.90Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$925MTotal addressable market
SAM$373MServiceable available market
SOM$81MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.8% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$925MLarge & growingTAM by 2033 at 9.8% CAGR
$373MServiceable nowreachable with today’s model
$81MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$721MBear6.4% CAGR
$925MBase9.8% CAGR
$1.18BBull12.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Area optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Specialty Pharmacy Services Market — a $2.44B market by 2033. Plan: grow share from 11.4% to 17.8%.
Market size · 2033$2.44Btotal addressable
Market CAGR5.9%2027–2033
Target share17.8%from 11.4% today
Revenue ambition$434Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.4% | 17.8% | At risk |
| Revenue | $261M | $434M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 35.7% | 39.2% | On track |
| Customer retention | 89.8% | 93.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Area capability
A defensible second engine — invest in Therapeutic Area to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Area
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $44M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Area
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Specialty Pharmacy Services Market conversation — a $5.19B market you can size, segment and defend in minutes.
Market size · 2033$5.19Btotal opportunity
Growth10.8%CAGR to 2033
Addressable buyers1,131+accounts in scope
Typical ROI7.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.1×return on cost, year one
< 3 mopayback period
$88K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
CVS Health Specialty PharmacyOptumRx (UnitedHealth Group)Express Scripts Specialty Pharmacy (Cigna)Walgreens Boots Alliance Specialty PharmacyAccredo Specialty Pharmacy (Express Scripts)Diplomat Pharmacy (now part of OptumRx)BioScrip Inc.Kaiser Permanente Specialty Pharmacy+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Specialty Pharmacy Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Specialty Pharmacy Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Specialty Microscope Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportSpecialty Lancets Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportSpecialty Gases for Life Sciences Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportSpecialty Dialysis Chair Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportSpecialty Diagnostic Enzyme Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportSpecialty Contact Lenses Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportSpecialty Biopharmaceutical Excipients Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportSpecialty Beds Market
Market size, share, segmentation and regional forecast.
$849M market · 2025 base year
View reportSpecialty Absorptive Dressings Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportSpecial Staining System Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportSpecial Stainer Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportSpecial Sponge for Negative Pressure Drainage Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.